Sio Gene Therapies combines cutting-edge science with bold imagination to develop genetic medicines that aim to radically improve the lives of patients. Its current pipeline of clinical-stage candidates includes the first potentially curative AAV-based gene therapies for GM1 gangliosidosis and Tay-Sachs/Sandhoff diseases, which are rare and uniformly fatal pediatric conditions caused by single gene deficiencies. The company is also expanding the reach of gene therapy to highly prevalent conditions such as Parkinson's disease, which affects millions of patients globally. Led by an experienced team of gene therapy development experts, and supported by collaborations with premier academic, industry and patient advocacy organizations, Sio is focused on accelerating its candidates through clinical trials to liberate patients with debilitating diseases through the transformational power of gene therapies.
Company profile
Ticker
SIOX
Exchange
Website
CEO
Pavan Cheruvu
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Axovant Gene Therapies Ltd., Axovant Sciences Ltd., Roivant Neurosciences Ltd.
SEC CIK
Corporate docs
Subsidiaries
Sio Europe Limited • Axovant Holdings Limited • Axovant Sciences GmbH ...
SIOX stock data
Latest filings (excl ownership)
DEFA14A
Additional proxy soliciting materials
16 Mar 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
15 Mar 23
DEFM14A
Proxy related to merger
21 Feb 23
DEFA14A
Additional proxy soliciting materials
14 Feb 23
8-K
Sio Gene Therapies Announces Fiscal Third Quarter 2022 Financial Results
14 Feb 23
10-Q
2023 Q3
Quarterly report
14 Feb 23
PREM14A
Preliminary proxy related to merger
8 Feb 23
DEFA14A
Additional proxy soliciting materials
14 Dec 22
8-K
Sio Gene Therapies Inc. Announces Board Approval of Plan of Complete Liquidation and Dissolution
14 Dec 22
8-K
Sio Gene Therapies Announces Fiscal Second Quarter 2022 Financial Results
10 Nov 22
Latest ownership filings
SC 13G/A
SUVRETTA CAPITAL MANAGEMENT, LLC
13 Feb 23
SC 13G
Rubric Capital Management LP
10 Feb 23
SC 13G/A
Consonance Capital Management LP
14 Feb 22
SC 13G/A
SUVRETTA CAPITAL MANAGEMENT, LLC
11 Feb 22
4
Parag V Meswani
10 Feb 22
4
David W. Nassif
10 Feb 22
3
Parag V Meswani
7 Feb 22
4
David W. Nassif
9 Dec 21
4
Pavan Cheruvu
9 Dec 21
4
Kristiina MD Vuori
19 Apr 21
Financial summary
| Quarter (USD) | Dec 22 | Sep 22 | Jun 22 | Mar 22 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Mar 22 | Mar 21 | Mar 20 | Mar 19 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 46.13 mm | 46.13 mm | 46.13 mm | 46.13 mm | 46.13 mm | 46.13 mm |
| Cash burn (monthly) | 1.64 mm | 3.08 mm | 1.34 mm | 2.38 mm | 1.64 mm | 3.04 mm |
| Cash used (since last report) | 5.06 mm | 9.49 mm | 4.13 mm | 7.33 mm | 5.06 mm | 9.37 mm |
| Cash remaining | 41.07 mm | 36.63 mm | 42.00 mm | 38.80 mm | 41.07 mm | 36.75 mm |
| Runway (months of cash) | 25.0 | 11.9 | 31.4 | 16.3 | 25.0 | 12.1 |
Institutional ownership, Q4 2022
34.7% owned by funds/institutions
| 13F holders | Current |
|---|---|
| Total holders | 36 |
| Opened positions | 6 |
| Closed positions | 7 |
| Increased positions | 6 |
| Reduced positions | 13 |
| 13F shares | Current |
|---|---|
| Total value | 7.65 bn |
| Total shares | 18.59 mm |
| Total puts | 0.00 |
| Total calls | 1.60 k |
| Total put/call ratio | – |
| Largest owners | Shares | Value |
|---|---|---|
| Rubric Capital Management | 7.00 mm | $3.05 bn |
| Newtyn Management | 3.00 mm | $1.31 bn |
| Tang Capital Management | 2.00 mm | $870.00 mm |
| Vanguard | 1.74 mm | $756.87 mm |
| MS Morgan Stanley | 1.51 mm | $657.89 mm |
| Geode Capital Management | 432.27 k | $188.00 k |
| JBF Capital | 429.60 k | $186.88 mm |
| Renaissance Technologies | 409.28 k | $178.00 k |
| BLK Blackrock | 390.39 k | $169.82 mm |
| Western Standard | 294.40 k | $128.06 mm |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 8 Feb 22 | Nassif David W. | RSU Common Stock | Grant | Acquire A | No | No | 0 | 546,500 | 0.00 | 546,500 |
| 8 Feb 22 | Parag V Meswani | RSU Common Stock | Grant | Acquire A | No | No | 0 | 153,700 | 0.00 | 153,700 |
| 8 Dec 21 | Nassif David W. | Common Stock | Payment of exercise | Dispose F | No | No | 1.42 | 6,294 | 8.94 k | 45,244 |
| 8 Dec 21 | Nassif David W. | Common Stock | Grant | Acquire A | No | No | 0 | 17,534 | 0.00 | 51,538 |
| 8 Dec 21 | Nassif David W. | RSU Common Stock | Sale back to company | Dispose D | No | No | 0 | 17,534 | 0.00 | 35,066 |
| 8 Dec 21 | Cheruvu Pavan | Common Stock | Payment of exercise | Dispose F | No | No | 1.42 | 14,884 | 21.14 k | 203,109 |
| 8 Dec 21 | Cheruvu Pavan | Common Stock | Grant | Acquire A | No | No | 0 | 37,567 | 0.00 | 217,993 |
| 8 Dec 21 | Cheruvu Pavan | RSU Common Stock | Sale back to company | Dispose D | No | No | 0 | 37,567 | 0.00 | 75,133 |